Navigation Links
Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundation's 2011 Spring Clinical Meetings
Date:3/7/2011

NEW YORK, March 7, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) today announced that the final dataset from the Phase 3 short-term clinical trial of Zerenex™ (ferric citrate) for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis has been selected for oral presentation at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings, to be held April 26-30, 2011 in Las Vegas, Nevada.  

The Zerenex data will be presented by David S. Goldfarb, M.D., Chief of Nephrology, New York VA Medical Center, Professor of Medicine & Physiology, NYU School of Medicine, in a presentation entitled "Advantages and Disadvantages of Existing Phosphate Binders."  This presentation will be the first part in a session entitled "Future Directions and Challenges for Phosphate Binders."  The session will take place on Thursday, April 28, 2011, 8:00am – 8:30am PT.  

On November 30, 2010, the Company issued a press release announcing positive top-line results from this Phase 3 short-term study.  

In accordance with the Company's Special Protocol Assessment (SPA) agreement with the FDA, the Phase 3 clinical program for Zerenex consists of two clinical studies, the completed short-term study, and a long-term safety and efficacy study that is currently ongoing.

About Keryx Biopharmaceuticals, Inc.  Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with approved therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex for the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector, Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5965
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
2. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
3. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
4. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
6. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
7. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
10. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), ... Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Executive Officer of the Company is scheduled to present on Tuesday, ... and the Chairman of the Board, Tony Holler ... ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... , ... Providing broad access to life-saving drugs and rewarding the innovators who ... to address this problem. , That was the message from Dana Goldman, PhD, Leonard ... University of Southern California, who served as the keynote speaker for Western University of ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke ... young adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions ... is “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t ... the next project in the company’s esteemed VISION House demonstration project series. Manifesting the ... the amount of resources they need to live affordably and abundantly without unduly taxing ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry , ... , an active lifestyle company that provides Human Performance Training and education to ... offers, first responders, military officers and others in service through the development and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
Breaking Medicine News(10 mins):